Jacobio, a China-based clinical-stage pharmaceutical company, announced on Sunday that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) in the United States for the company's self-developed global first-in-class drug Aurora A inhibitor JAB-2485.
The company is planning to start a Phase I/IIa clinical trial in patients with advanced solid tumours in the United States.
The product is a highly selective small molecule Aurora A inhibitor that can inhibit Aurora A activity at the cellular level, induce apoptosis and inhibit tumour growth. The inhibitory activity of Aurora A is one thousand times higher than that of Aurora B, and has potential to benefit patients with small cell lung cancer and triple negative breast cancer.
The company's self-developed JAB-2485 is the third Aurora A inhibitor enter into clinical stage in the United States.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML